Kodal Minerals PLC has acquired rights to up to 80% of the Asamankese lithium exploration project in Ghana, marking an expansion beyond its Mali operations. Early exploration shows high-grade lithium, with rock-chip samples up to 2.49% lithium oxide and historical samples reaching 3.02%. Kodal initially bought a 10% stake for $300,000 and plans staged investments over five years to increase ownership, contingent on exploration progress and feasibility studies. Fieldwork is underway, with diamond drilling expected to start before the end of 2026, targeting key prospects Amantra and Nfranta.
Kodal Minerals' expansion into lithium exploration in Ghana is the subject, with Pluang market data as of Oct 19, 2026 13:11 WIB. For readers following the Basic Materials sector, 63 of 83 US stocks traded on Pluang rose while 17 fell. Notable gainers include IAG at USD 18.09 (+6.10%), NG at USD 6.60 (+5.94%), and MT at USD 66.20 (+5.94%), with IAG showing the highest 1-day percentage increase.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
